MiMedx Addresses Misrepresentations In Seeking Alpha Article

February 7, 2014

MARIETTA, Ga., Feb. 7, 2014 /PRNewswire/ — MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha.

Shareholders should not rely on Seeking Alpha type articles regardless of whether they are positive or negative. The primary source of information should be the Company’s filings and press releases. Second, the analysts who follow the Company and make the investment in time to thoroughly analyze the information available should be relied upon. This recent post, and others like it, have had multiple false, misleading, and inaccurate statements.

MiMedx takes its investor disclosure responsibilities very seriously and is confident in the accuracy of those disclosures. If investors have any questions regarding the Company, please contact investor relations at 770-651-9066 or investorrelations@mimedx.com or contact the analysts that follow the Company.

About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 200,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.


Source: PR Newswire

comments powered by Disqus